NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), ...
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a ...
NEW YORK - TG Therapeutics, Inc. (NASDAQ:TGTX), a biopharmaceutical company with impressive gross profit margins of 87% and strong revenue growth of 31% over the last twelve months, announced Tuesday ...
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), ...
--TG Therapeutics, Inc., announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI, the company’ s anti-CD20 monoclonal antibody, in people with relapsing forms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback